Cargando…
A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy
INTRODUCTION: Apitegromab (SRK-015) is an anti-promyostatin monoclonal antibody under development to improve motor function in patients with spinal muscular atrophy, a rare neuromuscular disease. This phase 1 double-blind, placebo-controlled study assessed safety, pharmacokinetic parameters, pharmac...
Autores principales: | Barrett, Doreen, Bilic, Sanela, Chyung, Yung, Cote, Shaun M., Iarrobino, Ryan, Kacena, Katherine, Kalra, Ashish, Long, Kimberly, Nomikos, George, Place, Amy, Still, James Gordon, Vrishabhendra, Leela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189951/ https://www.ncbi.nlm.nih.gov/pubmed/33963971 http://dx.doi.org/10.1007/s12325-021-01757-z |
Ejemplares similares
-
A Sensitive and Selective Immunoassay for the Quantitation of Serum Latent Myostatin after In Vivo Administration of SRK-015, a Selective Inhibitor of Myostatin Activation
por: Cote, Shaun M., et al.
Publicado: (2019) -
Preclinical Safety Assessment and Toxicokinetics of Apitegromab, an Antibody Targeting Proforms of Myostatin for the Treatment of Muscle-Atrophying Disease
por: Welsh, Brian T., et al.
Publicado: (2021) -
Structural basis of specific inhibition of extracellular activation of pro- or latent myostatin by the monoclonal antibody SRK-015
por: Dagbay, Kevin B., et al.
Publicado: (2020) -
Nonclinical Development of SRK-181: An Anti-Latent TGFβ1 Monoclonal Antibody for the Treatment of Locally Advanced or Metastatic Solid Tumors
por: Welsh, Brian T., et al.
Publicado: (2021) -
Accuracy of the SRK/T Formula in Pediatric Cataract Surgery
por: Irfani, Irawati, et al.
Publicado: (2023)